iPSCs have great replicative ability and demonstrated potential to form functional cardiomyocytes (CMs). These CMs stand for a promising source for cell replacement therapy to treat heart disease, and they may act as a potent tool for drug discovery and disease modeling. Until now, a variety of approaches have been developed for producing iPSC-derived CMs and many are available in Creative Bioarray.
Creative Bioarray provides top quality service for directed-differentiation of iPSCs into cardiomyocytes using our proprietary induction protocol and reagents. We deliver ready-to-use, functional cardiomyocytes that are desirable in vitro models for high content toxicity and drug screening, and cell regeneration research. They are a feasible and physiologically relevant alternative to embryonic stem cell, primary cells, and animal models.
Workflow:
- Recovery, Expansion and Validation of iPSCs/ESCs
- Cardiomyocyte Differentiation
- Characterization of differentiated cells by immunocytochemical (ICC) staining: 2 biomarkers (cTNT; SMA)
Deliverables:
1. Lineage-committed cardiomyocytes differentiated from iPSCs.
2. Report containing results and data:
- Phase contrast images of parental iPSC lines after expansion (milestone 1); and differentiated cardiomyocytes
- Videos of beating cardiomyocytes (before cryopreservation)
- Antibody staining images of cardiomyocytes using anti-TNT anti-SMA antibodies
- Freeze-thaw viability and mycoplasma testing